+441518081136The Pharmacogenetics of mycophenolate mofetil in tunisian renal transplant patients
7th World Congress on Pharmacological and Toxicological Studies
December 14, 2022 | Webinar
Amani Abderahmene
Sahloul University Hospital, Tunisia
Posters & Accepted Abstracts : J Pharmacol Ther Res
Abstract:
Aim: The effects of variants in IMPDH, UGT1A9, UGT1A8, UGT2B7 and SLCO1B1 genes on the efficacy and safety of mycophenolate mofetil (MMF) in the Tunisian population were investigated. Materials & methods: A total of 245 kidney transplant patients being treated with MMF were recruited and cotreated with cyclosporine or tacrolimus. Genotyping was performed using the polymerase chain reactionrestriction fragment length polymorphism method. MMF, cyclosporine and tacrolimus trough levels were measured by immunoassay. The AUC (AUC0-12hMPA) was estimated by a Bayesian method. Results: In the tacrolimus-treated group, anemia and diarrhea were associated with the UGT1A9-98C and UGT1A9- 275T alleles, respectively (p<0.05). In the cyclosporinetreated group, leukopenia was associated with the SLCO1B1- 521T allele (p < 0.05). Both groups had an increased risk of rejection (p < 0.05) associated with the variant alleles of IMPDH2-3757T>C,UGT1A9-2152C>T and UGT1A9-275C>A and the common allele of SLCO1B1-388A>G. However, no significant association was found between the studied genotypes and AUC0-12hMPA or cotreatment levels. Conclusion: The results constitute preliminary evidence for the inclusion of the pharmacogenetics of MMF in kidney PR transplantation evaluations. Recent Publications 1. Amani Abderahmene, Amel Ellouz & Dorra Amor The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients PERSONALIZED MEDICINE VOL. 19, NO. 5 2. Lekshmy Srinivas, Noble Gracious & Radhakrishnan R. Nair Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients Frontiers in Pharmacology November 2021 | Volume 12.
PDF HTML